Zacks: Brokerages Expect Johnson & Johnson (NYSE:JNJ) to Post $2.55 EPS

Equities research analysts expect Johnson & Johnson (NYSE:JNJGet Rating) to announce earnings per share of $2.55 for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Johnson & Johnson’s earnings. The highest EPS estimate is $2.68 and the lowest is $2.41. Johnson & Johnson posted earnings of $2.48 per share in the same quarter last year, which indicates a positive year over year growth rate of 2.8%. The firm is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Johnson & Johnson will report full year earnings of $10.20 per share for the current year, with EPS estimates ranging from $10.15 to $10.27. For the next year, analysts anticipate that the business will report earnings of $10.74 per share, with EPS estimates ranging from $10.49 to $10.97. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Johnson & Johnson.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The firm had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. During the same period in the prior year, the company posted $2.59 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year.

A number of analysts have recently weighed in on JNJ shares. Citigroup lowered their price target on shares of Johnson & Johnson from $210.00 to $205.00 in a report on Tuesday, May 17th. Bank of America began coverage on shares of Johnson & Johnson in a report on Wednesday, March 2nd. They set a “neutral” rating for the company. Morgan Stanley cut their price target on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Raymond James lifted their target price on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, Sanford C. Bernstein cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their target price for the stock from $180.00 to $183.00 in a research note on Wednesday, March 16th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $187.86.

Shares of JNJ opened at $181.40 on Wednesday. The company has a market cap of $477.34 billion, a P/E ratio of 24.45, a P/E/G ratio of 2.87 and a beta of 0.66. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company’s fifty day simple moving average is $178.81 and its 200-day simple moving average is $171.12. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.49%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date is Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is 57.14%.

In other Johnson & Johnson news, insider William Hait sold 29,699 shares of Johnson & Johnson stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $183.58, for a total value of $5,452,142.42. Following the completion of the sale, the insider now owns 80,236 shares in the company, valued at approximately $14,729,724.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $176.25, for a total value of $4,173,776.25. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Magnolia Capital Management Ltd. grew its stake in Johnson & Johnson by 0.5% during the first quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after acquiring an additional 55 shares in the last quarter. Howard Financial Services LTD. lifted its position in Johnson & Johnson by 2.1% during the first quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock valued at $489,000 after purchasing an additional 57 shares during the last quarter. American Financial Advisors LLC lifted its position in Johnson & Johnson by 2.1% during the first quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock valued at $481,000 after purchasing an additional 57 shares during the last quarter. Capital Investment Counsel Inc lifted its position in Johnson & Johnson by 0.8% during the fourth quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock valued at $1,334,000 after purchasing an additional 59 shares during the last quarter. Finally, Kwmg LLC lifted its holdings in shares of Johnson & Johnson by 2.6% in the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after acquiring an additional 59 shares during the last quarter. 68.78% of the stock is currently owned by hedge funds and other institutional investors.

About Johnson & Johnson (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.